Stocks are a wild ride, but Veru Inc. (VERU) is doing something that feels like a high-stakes science experiment. Honestly, if you’ve been looking at the veru stock price lately, you’ve probably noticed it’s been bouncing around like a pinball. It’s sitting right around $2.33 as of January 14, 2026. That might not look like much compared to its old double-digit highs, but there is a massive story happening under the hood that the casual observer is totally missing.
Basically, Veru is trying to solve the "skinny fat" problem. You know how everyone and their cousin is on a GLP-1 drug like Wegovy or Zepbound? Those drugs are great for losing weight, but they have a nasty habit of eating away your muscle along with the fat. Veru’s lead drug, enobosarm, is designed to fix that.
The stock market is a cold-blooded place, and right now, it’s waiting to see if Veru can actually pull this off.
The Reality of the Veru Stock Price Today
Let’s get into the numbers because they tell a pretty blunt story. Today, the stock opened at $2.42 and has been drifting lower, hitting a low of $2.31 during the session. It’s a micro-cap world for these guys—we’re talking a market cap of about $37 million. That is tiny. When a company is this small, a single piece of news can send the price screaming up 50% or cratering it just as fast.
Look at the 52-week range: it’s been as high as $14.20 and as low as $2.10.
If you bought at the top, you’re hurting. But if you’re looking at it now, you’re seeing a company that just raised cash. They finished a public offering recently that pumped about $23.4 million into their bank account. That’s their "oxygen tank." It keeps the lights on and the trials running through the end of the year.
Why Analysts Are Acting So Strange
Here is the weird part. Most stocks trade somewhere near what analysts think they are worth. Not VERU.
The average price target from Wall Street analysts is currently sitting at $22.50. Some, like the folks at Oppenheimer and Canaccord Genuity, have even higher hopes. We’re talking about a forecasted upside of over 800%.
Why the massive gap? Because Veru is a "binary" play.
- Scenario A: The clinical trials for enobosarm work, and they partner with a giant like Eli Lilly or Novo Nordisk. The stock goes to the moon.
- Scenario B: The trials fail to show enough muscle preservation. The stock goes to zero.
There isn't much middle ground here, and that's why the veru stock price feels so stagnant right now. Investors are in "wait and see" mode.
📖 Related: Cal Bar Pass Rate: What Really Happened with the Recent Numbers
The Muscle-Sparing Secret Sauce
The whole investment thesis for Veru rests on a Phase 2b trial called PLATEAU. This study is supposed to start in early 2026. The goal is to show that when you take enobosarm alongside a GLP-1, you lose more fat but keep your muscle.
Muscle is metabolic currency. If you lose it, your metabolism slows down, and you gain the weight back the second you stop the shots. Veru thinks they have the key to making weight loss permanent and healthy.
What the FDA Actually Said
Earlier in late 2025, the FDA gave Veru some "regulatory clarity." That’s fancy talk for "we told them exactly what they need to do to get approved." The FDA confirmed that a 3mg dose of enobosarm is the way to go. More importantly, they said that showing "incremental weight loss" when added to a GLP-1 is an acceptable goal for approval.
This was a huge win for the company. It simplified the path. Before this, there was a lot of confusion about whether they had to prove muscle gain or just prevent muscle loss. Now the roadmap is clear.
👉 See also: Is Germany in Recession? Why Most People Get It Wrong in 2026
Financials: The Burning House
We have to talk about the money because it’s not all sunshine. Veru reported a net loss of over $22 million for fiscal year 2025. They are losing money every single day. Their revenue—mostly from their older sexual health products like the FC2 Internal Condom—is about $16 million a year. That doesn't even come close to covering their R&D costs.
They had about $15.8 million in cash back in September 2025. Without that recent $23 million capital raise, they would have been in serious trouble by now.
| Metric | Value (Approx) |
|---|---|
| Trailing EPS | -$2.20 |
| Next Earnings Date | Feb 12, 2026 |
| Institutional Ownership | ~22% |
| Short Interest | ~4.6% |
The short interest isn't incredibly high, which tells me the "bears" aren't aggressively betting against it—they’re just ignoring it. For a stock to move, it needs eyes. It needs volume. Right now, the volume is around 150,000 shares a day, which is pretty sleepy.
What Most People Get Wrong About VERU
A lot of people think Veru is just another "me-too" weight loss company. It’s not. They aren't trying to make another injection. They are making a pill that you take with the injection.
There’s also this misconception that their COVID-19 drug, sabizabulin, is their main driver. It’s not anymore. While they are still looking at sabizabulin for cardiovascular inflammation, the market has pivoted almost entirely to the obesity pipeline. If you’re still holding for a "COVID play," you’re living in 2022.
What Really Happens Next?
The next big catalyst is the February 12, 2026 earnings report. Don't look at the revenue—it’s going to be small. Look at the "burn rate." If they are spending too much money too fast, they’ll have to dilute the stock again by selling more shares. That’s the biggest risk for current shareholders.
Also, keep an eye on the start of the PLATEAU trial. If they announce the first patient has been dosed, it might give the veru stock price the jolt it needs to break out of this $2.30 range.
✨ Don't miss: Philadelphia Tax Abatement: Why the Rules Changed and What You’re Actually Saving
Actionable Insights for Your Watchlist
If you’re thinking about jumping in, keep these points in mind:
- High Volatility: This is not a "set it and forget it" stock for your 401k. It’s a speculative biotech play.
- Trial Timing: Data from the PLATEAU trial isn't expected until early 2027. That’s a long time to wait.
- The 3mg Dose: This is the "Goldilocks" dose. Watch for any safety data updates regarding liver enzymes, as that was a minor red flag in earlier, higher-dose studies.
- Cash Runway: They likely have enough money to get through 2026, but not much further. Expect another capital raise if the stock price spikes.
The biotech sector is littered with companies that had "great ideas" but ran out of money. Veru has a legitimate shot at a massive market, but the clock is ticking.
Next Steps for Investors:
- Check the SEC filings for the specific terms of the December 2025 public offering to see if there are warrants that might cap the stock's upside.
- Monitor the February 12th earnings call for updates on the "modified release" oral formulation, which could extend their patent protection to 2045.
- Compare Veru's progress with competitors like Biohaven or Altimmune, who are also chasing the "muscle-sparing" weight loss crown.